CA-CROWN-BIOSCIENCE
7.1.2021 19:18:22 CET | Business Wire | Press release
Crown Bioscience, a JSR Life Sciences company, today announced the expansion of their state-of-the-art NGS capabilities, together with the launch of proprietary NGS panel services , providing increased opportunities for pharmaceutical partners to better understand drug mechanisms of action (MOA) and to develop predictive biomarkers for their investigational drug candidates.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210107005802/en/
The newly built, comprehensive suite of NGS capabilities provides clients with a streamlined multi-omics workflow of high-quality services, enabling full genomic understanding, including global gene expression, mutations, and genomic structures. This is a significant addition to CrownBio’s current preclinical and translational services, allowing clients greater insight into disease mechanisms, drug MOAs, and responder patient populations, to ultimately accelerate successful development of effective therapies.
The expanded services have been established at the Company’s Center of Translational Science in Suzhou, China, to meet increased client demand for whole genome sequencing (WGS), including Illumina’s Novaseq 6000 and BGI’s MGISEQ-2000 second generation sequencing platform. PacBio’s third generation Sequel Ⅱ sequencing platform allows for high throughput, high accuracy long-read NGS, and Bionano’s Saphyr® Genome Imaging enables large structural variant analysis and genome mapping. Comprehensive data analysis pipelines have also been built, together offering highly sensitive genome assembly and discovery algorithms.
“With our range of validated services, we can help drug developers improve the accuracy, sensitivity and speed at which they progress their new agent programs via discovery of MOAs and predictive biomarkers,” said Henry Li, PhD, chief scientific officer at CrownBio. “This type of multi-omics data is essential to understand the clinical populations that respond to anticancer agents and progress cancer treatments.”
In addition to the validated commercial platforms, CrownBio has also developed various powerful biomedical applications using NGS platforms, including NGS panels for bio-sample authentication, contamination detection and quantification, mouse tumor microenvironment profiling and metagenomic sequencing services for microbiome analysis. Custom NGS services are also available for clients who wish to utilize CrownBio’s expertise and large model biobank.
“Quality downstream applications are key to maximizing the full potential of in vivo study results, including our wealth of historical model and treatment data,” said Sheng Guo, PhD, head of bioinformatics at CrownBio. “These are leveraged by a highly experienced team and a proprietary, published algorithm to provide important biomarker discovery and drug mechanism probing services.”
These NGS services are available for client use immediately including our newly launched mouse I/O profiling targeted RNA-seq panel . The panel will allow deep profiling of the immunogenomics of murine tumor-immune interactions through the measurement of 1080 transcripts from a single sample.
About Crown Bioscience Inc.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:
● https://www.jsrlifesciences.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005802/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vena To Acquire Acterys, Creating a New Category of Enterprise Performance Management: Orchestrated Planning3.2.2026 17:00:00 CET | Press release
The acquisition unites finance foresight and IT innovation in the first Microsoft-native Orchestrated Planning environment, helping enterprises plan better and achieve more by turning strategy into aligned execution in real time. Vena, the only complete FP&A platform powered by agentic AI and purpose-built to amplify the Microsoft technology ecosystem, today announced it has entered into a definitive agreement to acquire Managility Pty Ltd, operating as Acterys (“Acterys”), the industry’s leading Power BI–based operational planning and app development platform, subject to customary closing conditions and regulatory approval. This acquisition unlocks a category-defining way for enterprises to combine planning, analytics, and application development within the Microsoft tools they already trust to run their business. By combining Vena’s Excel-native financial planning and analysis (FP&A) capabilities with Acterys’ proprietary Power BI write-back engine and unified analytics within Micros
Volante Technologies named a Leader in Gartner® Magic Quadrant™ for Banking Payment Hub Platforms3.2.2026 16:15:00 CET | Press release
Volante believes its solutions provide complete always-on payment processing support for banks and financial institutions across all tiers Volante Technologies, the global leader in Payments as a Service (PaaS), today announced its recognition as a Leader in the 2026 Gartner® Magic Quadrant™ for Banking Payment Hub Platforms, which evaluates vendors based on Ability to Execute and Completeness of Vision. In Volante’s view, Gartner positioned them as a Leader based on their capacity to support enterprise-scale payment processing in banks and financial institutions across multiple regions, deployment models, and operational environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203149834/en/ This graphic was published by Gartner, Inc. as part of a larger research document and should be evaluated in the context of the entire document. As the highest positioned provider in Ability to Execute, Volante believes its AI-pow
Toptal Ranked #1 Most Reliable Professional Services Company in America by Newsweek3.2.2026 16:00:00 CET | Press release
Toptal, the world’s largest fully remote workforce, has been ranked the #1 most reliable professional services company in America on the America’s Most Reliable Companies 2026 list by Newsweek and Statista. The list ranks top US companies based on trust, dependability, and consistent performance in their industry. In Newsweek’s ranking of 300 companies across all industries, Toptal took 10th place, right behind Bank of America and Oracle, which tied for 9th. As the most reliable professional services organization in America, Toptal, which ranked 11th in absolute rankings across all companies, placed well ahead of companies like Accenture (33), Deloitte (39), and Cognizant (66). The America’s Most Reliable Companies 2026 ranking is based on an independent survey of more than 80,000 evaluations submitted by 2,400 business decision-makers at America’s largest companies, including Apple, Dropbox, Johnson & Johnson, and UPS, making this recognition an especially meaningful indicator of prod
HTEC Research Reveals the Real AI Scaling Challenge: It’s Not the Technology3.2.2026 15:46:00 CET | Press release
Global executive survey finds AI momentum is real—but leadership alignment, capability gaps, and ROI clarity are slowing enterprise impact AI has moved from ambition to action. Every organization is deploying it. Yet for most enterprises, the real challenge is only just beginning. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260203951136/en/ HTEC, a global AI‑first provider of software and hardware design and engineering services, released Executive Summary: A Cross‑Industry View of the State of AI in 2025, a global research report capturing how senior executives are navigating the next phase of AI transformation—and why scaling value remains elusive. Today, HTEC, a global AI‑first provider of software and hardware design and engineering services, released Executive Summary: A Cross‑Industry View of the State of AI in 2025, a global research report that captures how senior executives are navigating the next phase of AI tra
Yubico Reveals 265% ROI and 99.99% Reduction in Risk of Exposure to Addressable Breach Risk Costs According to Total Economic Impact Study3.2.2026 15:00:00 CET | Press release
Effectiveness of Yubico’s technology: $5.3 million Net Present Value and $7.3 million in total benefits over three years, driven by 80% faster authentication and reduced help desk burden Yubico (NASDAQ STOCKHOLM: YUBICO), a modern cybersecurity company and creator of the most secure passkeys, today announced the results of a commissioned Total Economic Impact™ (TEI) of Yubico YubiKeys study conducted by Forrester Consulting. The study, comprised of interviews with global enterprises with over 5,000 employees, found that a composite organization based on interviewed customers achieved a 265% return on investment (ROI) and a net present value (NPV) of $5.3 million over three years by replacing traditional multi-factor authentication (MFA) and one-time passwords (OTPs) with phishing-resistant YubiKeys. In an era of high-quality deepfakes and generative AI-driven extortion, the study shows a critical shift in cybersecurity: traditional MFA is no longer sufficient to stop modern MFA-bypass
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom